SEC Tracker
Get the app

Ultragenyx Pharmaceutical RARE

Ultragenyx settles patent dispute with Navinta

Item 8.01 Other events

Form
8-K
Filed
Importance
Routine
  1. Settlement with Navinta resolves DOJOLVI patent litigation
  2. Navinta gets non-exclusive license to market generic DOJOLVI starting 2033
  3. Other DOJOLVI patent cases remain pending
  4. Settlement to be submitted to FTC and DOJ

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Ultragenyx Pharmaceutical files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Avidity Biosciences RNAM public float $3.4B, Jun 30, 2025
  2. PERRIGO PRGO public float $3.7B, Jun 27, 2025
  3. Vaxcyte PCVX public float $3.7B, Jun 30, 2025
  4. Rhythm Pharmaceuticals RYTM public float $3.8B, Jun 30, 2025
  5. Viking Therapeutics VKTX public float $3.0B, Jun 30, 2025